Biodistribution of Native and Nanoformulated Innate Defense Regulator Peptide 1002
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Biodistribution of Native and Nanoformulated Innate Defense Regulator Peptide 1002. / Esposito, Tullio V.F.; Blackadar, Colin; Wu, Lan; Rodríguez-Rodríguez, Cristina; Haney, Evan F.; Pletzer, Daniel; Saatchi, Katayoun; Hancock, Robert E.W.; Häfeli, Urs O.
I: Molecular Pharmaceutics, Bind 21, Nr. 6, 2024, s. 2751-2766.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Biodistribution of Native and Nanoformulated Innate Defense Regulator Peptide 1002
AU - Esposito, Tullio V.F.
AU - Blackadar, Colin
AU - Wu, Lan
AU - Rodríguez-Rodríguez, Cristina
AU - Haney, Evan F.
AU - Pletzer, Daniel
AU - Saatchi, Katayoun
AU - Hancock, Robert E.W.
AU - Häfeli, Urs O.
N1 - Publisher Copyright: © 2024 American Chemical Society.
PY - 2024
Y1 - 2024
N2 - Innate defense regulator-1002 (IDR-1002) is a synthetic peptide with promising immunomodulatory and antibiofilm properties. An appreciable body of work exists around its mechanism of action at the cellular and molecular level, along with its efficacy across several infection and inflammation models. However, little is known about its absorption, distribution, and excretion in live organisms. Here, we performed a comprehensive biodistribution assessment with a gallium-67 radiolabeled derivative of IDR-1002 using nuclear tracing techniques. Various dose levels of the radiotracer (2-40 mg/kg) were administered into the blood, peritoneal cavity, and subcutaneous tissue, or instilled into the lungs. The peptide was well tolerated at all subcutaneous and intraperitoneal doses, although higher levels were associated with delayed absorption kinetics and precipitation of the peptide within the tissues. Low intratracheal doses were rapidly absorbed systemically, and small increases in the dose level were lethal. Intravenous doses were rapidly cleared from the blood at lower levels, and upon escalation, were toxic with a high proportion of the dose accumulating within the lung tissue. To improve biocompatibility and prolong its circulation within the blood, IDR-1002 was further formulated onto high molecular weight hyperbranched polyglycerol (HPG) polymers. Constructs prepared at 5:1 and 10:1 peptide-to-polymer ratios were colloidally stable, maintained the biological profile of the peptide payload and helped reduce red blood cell lysis. The 5:1 construct circulated well in the blood, but higher peptide loading was associated with rapid clearance by the reticuloendothelial system. Many peptides face pharmacokinetic and biocompatibility challenges, but formulations such as those with HPG have the potential to overcome these limitations.
AB - Innate defense regulator-1002 (IDR-1002) is a synthetic peptide with promising immunomodulatory and antibiofilm properties. An appreciable body of work exists around its mechanism of action at the cellular and molecular level, along with its efficacy across several infection and inflammation models. However, little is known about its absorption, distribution, and excretion in live organisms. Here, we performed a comprehensive biodistribution assessment with a gallium-67 radiolabeled derivative of IDR-1002 using nuclear tracing techniques. Various dose levels of the radiotracer (2-40 mg/kg) were administered into the blood, peritoneal cavity, and subcutaneous tissue, or instilled into the lungs. The peptide was well tolerated at all subcutaneous and intraperitoneal doses, although higher levels were associated with delayed absorption kinetics and precipitation of the peptide within the tissues. Low intratracheal doses were rapidly absorbed systemically, and small increases in the dose level were lethal. Intravenous doses were rapidly cleared from the blood at lower levels, and upon escalation, were toxic with a high proportion of the dose accumulating within the lung tissue. To improve biocompatibility and prolong its circulation within the blood, IDR-1002 was further formulated onto high molecular weight hyperbranched polyglycerol (HPG) polymers. Constructs prepared at 5:1 and 10:1 peptide-to-polymer ratios were colloidally stable, maintained the biological profile of the peptide payload and helped reduce red blood cell lysis. The 5:1 construct circulated well in the blood, but higher peptide loading was associated with rapid clearance by the reticuloendothelial system. Many peptides face pharmacokinetic and biocompatibility challenges, but formulations such as those with HPG have the potential to overcome these limitations.
KW - biodistribution
KW - hyperbranched polyglycerol
KW - IDR-1002
KW - nuclear tracing
KW - peptide
KW - radiolabeled peptide
KW - radiotracer
KW - SPECT/CT
U2 - 10.1021/acs.molpharmaceut.3c01169
DO - 10.1021/acs.molpharmaceut.3c01169
M3 - Journal article
C2 - 38693707
AN - SCOPUS:85192250925
VL - 21
SP - 2751
EP - 2766
JO - Molecular Pharmaceutics
JF - Molecular Pharmaceutics
SN - 1543-8384
IS - 6
ER -
ID: 395081754